Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Practice Effects and Amyloid Imaging with Flutemetamol
NCT01202994Phase 2Completed
- Sponsor
- University of Utah
- Start
- May 2011
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flutemetamol in Alzheimer's disease (AD), sponsored by University of Utah. Primary endpoint: Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan. Started May 2011; status: completed.
02
Drugs
flutemetamol
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01202994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01202994.